PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain)
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain). PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial. 2279
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020
Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine Source: Eur Respir J 2002; 19: 611-616 Year: 2002
Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects Source: Eur Respir J 2008; 31: 311-319 Year: 2008
Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
The adenosine A2A -Receptor is not involved in adenosine induced bronchoconstriction in asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
Beyond the dogma: novel β2-adrenoceptor signalling in the airways Source: Eur Respir J 2006; 27: 1286-1306 Year: 2006
Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis Source: Eur Respir J 2001; 17: 64-70 Year: 2001
An improved bronchial provocation test with dry powder adenosine instead of nebulised adenosine monophosphate (AMP) Source: International Congress 2017 – Monitoring asthma control Year: 2017
Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response Source: Eur Respir J 2003; 22: Suppl. 45, 204s Year: 2003
The role of CPA (adenosine A1 agonist) in airway reflexes Source: Annual Congress 2004 - Neural regulation of airways and cough Year: 2004
Effect of adenosine 5´-triphosphate (ATP) challenge vs. adenosine 5´-monophosphate (AMP) on the threshold of capsaicin-induced cough in healthy non-smokers, current smokers and patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 708s Year: 2004
The bronchoprotective effects of levocetirizine on adenosine monophosphate challenge in patients with atopic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004
Adenosine 5’ – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in current smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
Cellular and gas exchange responses to adenosine 5‘-monophosphate (AMP) challenge in mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids Source: Eur Respir J, 50 (2) 1700670; 10.1183/13993003.00670-2017 Year: 2017
Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 502s Year: 2002
Adenosine 5' – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in healthy non-smokers and patients with mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 350s Year: 2003
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Effects of salbutamol on gas exchange abnormalities and sputum neutrophilia induced by adenosine 5‘-monophosphate (AMP) in mild asthma Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006